Plain-language overview
PT-141 (bremelanotide) is a melanocortin receptor agonist. It is FDA-approved as Vyleesi for acquired, generalized hypoactive sexual desire disorder in premenopausal women. It is offered as an injectable.
Mechanism & background
PT-141 activates central melanocortin receptors (MC4R) involved in sexual-response signaling — a mechanism distinct from PDE5 inhibitors.
Class: Bremelanotide — melanocortin receptor agonist
Where this may fit
Discussed in sexual-health contexts. Eligibility for any individual is determined by a licensed clinician.
Safety screening & clinician review
Every option below begins with a screening-led intake and review by a licensed clinician through our partner workflow. Transient nausea and blood-pressure effects are described in the literature. Suitability and prescribing are determined by a licensed clinician through partner workflows. YourHealthRx does not diagnose, prescribe, or determine dosing.